MD MPH - Onxeo SA CEO Pres
| C4X Stock | EUR 0.07 0.01 16.88% |
Insider
MD MPH is CEO Pres of Onxeo SA
| Age | 49 |
| Phone | 33 1 45 58 76 00 |
| Web | https://www.onxeo.com |
Onxeo SA Management Efficiency
The company has return on total asset (ROA) of (0.1108) % which means that it has lost $0.1108 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3966) %, meaning that it generated substantial loss on money invested by shareholders. Onxeo SA's management efficiency ratios could be used to measure how well Onxeo SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| James Hoffman | Reliance Steel Aluminum | 64 | |
| Melissa Moore | Moderna | N/A | |
| Karla Lewis | Reliance Steel Aluminum | 57 | |
| Tracey Franklin | Moderna | 39 | |
| Suzanne Bonner | Reliance Steel Aluminum | 48 | |
| Erik Fallstrom | SIVERS SEMICONDUCTORS AB | 56 | |
| William II | Reliance Steel Aluminum | 55 | |
| James Mock | Moderna | 46 | |
| Juan Andres | Moderna | 58 | |
| Stephen MD | Moderna | 47 | |
| FCA FCA | Superior Plus Corp | 68 | |
| Israel Ruiz | Moderna | 47 | |
| Elizabeth Tallett | Moderna | 70 | |
| Tomas Duffy | SIVERS SEMICONDUCTORS AB | 62 | |
| Bjorn Norrbom | SIVERS SEMICONDUCTORS AB | 72 | |
| Robert Green | SIVERS SEMICONDUCTORS AB | 60 | |
| Marcello Damiani | Moderna | 49 | |
| Tal Zaks | Moderna | 53 | |
| Harry Kanwar | Superior Plus Corp | N/A | |
| Therese Holm | Norsk Hydro ASA | N/A | |
| Sean Mollins | Reliance Steel Aluminum | 44 | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 |
Onxeo SA Leadership Team
Elected by the shareholders, the Onxeo SA's board of directors comprises two types of representatives: Onxeo SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onxeo. The board's role is to monitor Onxeo SA's management team and ensure that shareholders' interests are well served. Onxeo SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onxeo SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elisabeth Carstensen, Director of Alliance Management, Member of the Executive Committee | ||
| Russell Greig, Independent Member of the Board | ||
| Remi Droller, Member of the Board - Representative of Kurma Life Science Partners | ||
| Daniele GuyotCaparros, Independent Member of the Board | ||
| Michel Forest, Vice President Quality Qualified Person and Member of the Executive Committee | ||
| Caroline Lemarchand, Preclinical R&D Director, Member of the Executive Committee | ||
| Olivier Beaumont, Chief Medical Officer, Member of the Executive Committee | ||
| Aude Michel, Director of Legal Affairs, Agreements and Licensing, Member of the Executive Committee | ||
| Huiping Jiang, VP Assurance | ||
| Sonia Vallons, Quality Assurance Director, Member of the Executive Committee | ||
| Thomas Hofstaetter, Independent Member of the Board | ||
| MD MPH, CEO Pres | ||
| Delphine Lucas, Regulatory Affairs Director, Member of the Executive Committee | ||
| Francoise Bono, Chief Scientific Officer, Member of the Executive Committee | ||
| Nicolas Trebouta, Member of the Board - Permanent Representative of Financiere de la Montagne | ||
| Audrey LegentilDumery, Director of Human Resources, Member of the Executive Committee | ||
| Judith Greciet, Chief Executive Officer, Member of the Executive Committee, Member of the Board | ||
| Nicolas Fellman, Vice President, Chief Financial Officer, Member of the Executive Committee | ||
| David Solomon, Independent Member of the Board | ||
| Joseph Zakrzewski, Non-Executive Chairman of the Board | ||
| Louis Kayitalire, Vice President Head of Research & Development | ||
| Philippe Maitre, Executive Vice President and Chief of U.S. Operations | ||
| Nicolas Fellmann, CFO Director |
Onxeo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onxeo SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 5.34 M | |||
| Shares Outstanding | 111.06 M | |||
| Shares Owned By Insiders | 13.25 % | |||
| Shares Owned By Institutions | 12.72 % | |||
| Price To Earning | 50.90 X | |||
| Price To Book | 0.48 X | |||
| Price To Sales | 5.35 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Onxeo Stock
Onxeo SA financial ratios help investors to determine whether Onxeo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Onxeo with respect to the benefits of owning Onxeo SA security.